Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.

Humanized monoclonal antibodies

3 mAbs (hematological malignancies and/or solid tumors)

New humanized monoclonal antibodies (mAbs), against newly identified antigen oncology targets, acting through Antibody Dependent Cell Cytotoxicity (ADCC) or as Antibody Drug Conjugated (ADC-antibody linked to a toxin) will be developed.

Selective and high affinity mAbs are being generated by an external partner.

Characterization of these mAbs in terms of binding characteristics, in vitro efficacy (ADCC, cytotoxicity, internalization), in vivo efficacy (xenograft models) and exploratory toxicology are ongoing.

Menarini will be responsible for: (i) development and commercial manufacturing, (ii) regulatory non-clinical development, (iii) clinical development phase I to phase III and (iv) regulatory submission to main Regulatory Agencies.

According to the agreement with OBT for the development and commercialization of 5 Antibodies, 2 of them are in Phase I  clinical trial  (MEN1112)  and Preclinical development (MEN1309)

Press Release 29/10/2012

Therapeutic Areas


Discover all of Menarini's products marketed in Italy.




Advanced Technology


The Menarini Group


Discover the leading Italian pharmaceutical company in the world.


Quality first


Quality: point of departure and arrival for our drugs.